Proton pump inhibitor use associated with an increased risk of gout: A population‐based case–control study

Abstract Objectives In previous reports, proton pump inhibitor (PPI) use increased the risk of gout. However, there is no epidemiological study investigating this association. We aimed to examine the potential impact of PPI treatment on the risk of developing gout. Methods A population‐based case–control study was performed using a Longitudinal Health Insurance Database 2000 from Taiwan (population 23 million). We identified gout cases and non‐gout controls through propensity score matching at 1:1, which was matched by sex and age. We used a conditional logistic regression model to estimate an odds ratio and 95% confidence intervals (CI) for gout population versus controls. Results Esomeprazole increased the risk of gout after adjusting confounding variables (adjusted odds ratio [aOR] 1.3; 95% CI 1.0–1.6). The risk of gout was highest within 30 days of PPI treatment (aOR 1.7; 95% CI 1.4–1.9) and attenuated thereafter. The risk of gout was increased among female users of PPI compared with male users (aOR 2.2; 95% CI 1.7–2.8). The aOR of gout in people with PPI use was higher in middle‐aged individuals (41–60 years: aOR 2.1; 95% CI 1.7–2.7) than in the older group (≥60 years: aOR 1.8; 95% CI 1.5–2.2). Conclusions Our findings provide population‐level evidence for the hypothesis that PPI treatment is positively associated with the risk of developing gout. Further research on the mechanism underlying this association is warranted.